2BB score and signals
Gyre Therapeutics, Inc.’s current 2BB score is 32 out of 100, built from the signal categories below.
| Signal | Score | Reading |
|---|
| Activity | 15 | Very Low |
| Momentum | 43 | Stable |
| Financial strength | 39 | Weak |
| Quality | 100 | Very Strong |
| Risk | 40 | Low |
Company facts
| Headquarters | Winston-Salem, North Carolina, United States |
| Founded | 1997 |
| Employees | 625 |
| 52-week range | $5.44 – $9.42 |
Recent earnings
| Report date | EPS actual | EPS estimate | Revenue actual | Revenue estimate |
|---|
| 2026-11-05 | — | -0.102 | — | $28.97M |
| 2026-08-18 | — | -0.0918 | — | $27.02M |
| 2026-05-07 | -0.045 | -0.0748 | $22.52M | $32.24M |
| 2026-03-12 | 0.05 | 0.0578 | $37.20M | $36.15M |
Related companies
